P-6250
Transplantation and Cellular Therapy | 2025
CRS or ICANS are rare beyond 2 weeks after lisocabtagene maraleucel infusion: Data from clinical trials and the real-world setting.
Hunter BD, Lunning MA, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M
PubMed
PMID: 41235976
CIBMTR Study #: CS24-09a